MedTrace Logo

Pharmacokinetics and Clinical Response of Tolvaptan in Neurocritical Care Patients

NCT02215148 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2016-09-08

No results posted yet for this study

Summary

To assess the pharmacokinetic profile of tolvaptan in critically ill acute brain injury patients and to secondarily evaluate the clinical response and safety of tolvaptan in acute brain injured patients

Conditions

Interventions

DRUG

Tolvaptan

Sponsors & Collaborators

  • Otsuka America Pharmaceutical

    collaborator INDUSTRY

  • Medical University of South Carolina

    collaborator OTHER

  • Barnes-Jewish Hospital

    collaborator OTHER

  • University of North Carolina, Chapel Hill

    lead OTHER

Principal Investigators

  • Kathryn A Morbitzer, PharmD · University of North Carolina, Chapel Hill

  • Denise H. Rhoney, PharmD · University of North Carolina, Chapel Hill

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2016-08-31
Completion
2016-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02215148 on ClinicalTrials.gov